Menu Search
Equities

Haemonetics Corp

HAE:NYQ

Haemonetics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)93.38
  • Today's Change1.98 / 2.17%
  • Shares traded1.24m
  • 1 Year change+8.43%
  • Beta0.3895
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Haemonetics Corp had little change in net income (from 115.40m to 117.56m) despite revenues that grew 12.01% from 1.17bn to 1.31bn.
Gross margin54.02%
Net profit margin9.10%
Operating margin12.30%
Return on assets5.46%
Return on equity13.97%
Return on investment6.19%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Haemonetics Corp fell by 105.67m. However, the company earned 181.75m from its operations for a Cash Flow Margin of 13.88%. In addition the company generated 38.16m cash from financing while 322.39m was spent on investing.
Cash flow per share4.54
Price/Cash flow per share20.05
Book value per share17.44
Tangible book value per share-4.47
More ▼

Balance sheet in USDView more

Haemonetics Corp has a Debt to Total Capital ratio of 58.23%, a lower figure than the previous year's 83.78%.
Current ratio3.49
Quick ratio2.09
Total debt/total equity1.39
Total debt/total capital0.5823
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 1.91%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)17.09
EPS (TTM) vs
TTM 1 year ago		-3.96
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.